Equities analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will announce $3.10 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Unum Therapeutics’ earnings, with estimates ranging from $1.80 million to $4.41 million. Unum Therapeutics posted sales of $1.67 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 85.6%. The firm is expected to report its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that Unum Therapeutics will report full year sales of $13.82 million for the current financial year, with estimates ranging from $8.30 million to $17.60 million. For the next year, analysts expect that the business will report sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last released its earnings results on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.15 million.
A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Unum Therapeutics in a research report on Tuesday, May 14th. Finally, SunTrust Banks dropped their price target on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research report on Friday, March 29th. They noted that the move was a valuation call. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.60.
NASDAQ:UMRX traded up $0.43 during mid-day trading on Wednesday, hitting $2.62. The company had a trading volume of 4,133,306 shares, compared to its average volume of 109,835. Unum Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $17.66. The company has a fifty day moving average price of $3.01. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $65.96 million, a price-to-earnings ratio of -1.88 and a beta of 1.77.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Unum Therapeutics by 281.5% during the fourth quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock worth $6,733,000 after buying an additional 1,129,262 shares in the last quarter. Sectoral Asset Management Inc grew its holdings in shares of Unum Therapeutics by 19.4% during the fourth quarter. Sectoral Asset Management Inc now owns 1,250,145 shares of the company’s stock worth $5,501,000 after buying an additional 203,200 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Unum Therapeutics by 312.6% during the fourth quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock worth $786,000 after buying an additional 135,345 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of Unum Therapeutics during the fourth quarter worth about $565,000. Finally, Wasatch Advisors Inc. grew its holdings in shares of Unum Therapeutics by 64.5% during the first quarter. Wasatch Advisors Inc. now owns 254,449 shares of the company’s stock worth $1,117,000 after buying an additional 99,814 shares in the last quarter. 47.27% of the stock is currently owned by institutional investors.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Further Reading: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.